Funding Daily Summary
Funding Daily Summary: What Happened on October 23, 2026
Lycia prices $318 million IPO to fund three protein degraders
The offering is intended to support medicines for allergic conditions and Graves’ disease.
Today in brief
Lycia priced a $318 million initial public offering to support three protein-degrading medicines in development.1 The medicines are being developed for allergic conditions and Graves’ disease.1
Lycia prices $318 million IPO for three drug programs
Lycia priced its initial public offering at $318 million.1 Proceeds from the upsized offering are intended to support three protein-degrading medicines for allergic conditions and Graves’ disease.1